Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
PaperCitations, authors & open-access status
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 350 citations, 2023 year and hybrid oa status.
350
Citations
2023
Year
hybrid
OA Status